Innovative Army Vaccine Aims to Combat All Covid Variants
Written on
Chapter 1: Introduction to the SpFN Vaccine
In a pivotal moment amidst the rise of the Omicron variant and ongoing vaccine skepticism, the U.S. Army has introduced a groundbreaking vaccine. Developed at the Army's Walter Reed Hospital, this vaccine is currently in clinical trials and holds the potential to significantly change the course of the pandemic.
Section 1.1: Development of the Spike Ferritin Nanoparticle (SpFN)
The Spike Ferritin Nanoparticle (SpFN) vaccine has been in development for two years. Early on, the research team at Walter Reed opted for an innovative approach to create a versatile vaccine platform. They engineered a nanoparticle framework to which they can attach various spike proteins, akin to assembling with Lego blocks. This method allows for the rapid adaptation of the vaccine to combat emerging variants without starting from scratch.
For instance, if a new variant like Rho arises, scientists can simply add the corresponding spike to the existing vaccine substrate. This design not only aims to protect against multiple Covid variants but also has implications for combating other coronaviruses, such as those causing the common cold.
Section 1.2: Need for Advanced Vaccines
The emergence of numerous human coronaviruses in the last twenty years, along with the recent proliferation of SARS-CoV-2 variants, highlights the urgent requirement for next-generation vaccines that can provide broad immunity against various coronavirus strains.
“Our goal is to develop a ‘pan-coronavirus’ vaccine technology that can deliver safe, effective, and long-lasting protection against multiple strains and species,” states Dr. Kayvon Modjarrad, a co-inventor of the vaccine.
Chapter 2: Clinical Trials and Future Prospects
SpFN has already demonstrated strong antibody responses during animal trials against SARS and has entered human clinical trials as of April. However, progress has been somewhat hindered by challenges in recruiting participants who have not received prior vaccinations or been infected with Covid-19.
In the coming weeks, Dr. Modjarrad anticipates sharing preliminary findings from the human trials, which could provide further insights into the vaccine's effectiveness.
The first video elaborates on the development of a universal coronavirus vaccine at the Walter Reed Army Institute of Research.
The second video features Army scientists discussing their experimental Covid-19 vaccine on NBC Nightly News.
Section 2.1: A Second Vaccine in Development
As if that were not enough, researchers are also exploring a second vaccine that utilizes smaller segments of the spike proteins, known as the Spike Receptor-Binding Domain Ferritin Nanoparticle (RFN). Should this vaccine prove successful, it could offer an even more robust and effective solution against Covid-19.
Reflections
I recently ordered a 3M N100 mask, capable of filtering out over 99% of particles. While I’m concerned about the current state of affairs, I'm determined to endure and even thrive. My spirits were lifted when I learned about the Walter Reed vaccine, which suggests we might finally conquer this relentless pandemic with just a booster shot every few months. If it's backed by the Army, perhaps even the skeptics will be encouraged to get vaccinated.
For more in-depth stories, consider joining Medium, where you can access articles from thousands of writers. A portion of your subscription fee supports my work at no extra cost to you.
References
- Series of preclinical studies supports the Army’s pan-coronavirus vaccine development strategy — US Army
- SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults — NIH ClinicalTrials.gov
- US Army Creates Single Vaccine Effective Against All COVID & SARS Variants, Researchers Say — Defense One